<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509600</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0215</org_study_id>
    <nct_id>NCT00509600</nct_id>
  </id_info>
  <brief_title>Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia</brief_title>
  <official_title>Phase IIA Window Study of Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

      1.1 Estimate rate of response and define acute toxicity to etanercept used in an up-front
      phase II window in newly diagnosed or relapsed JMML.

      1.2 Determine if response to Tumor Necrosis Factor (TNF) blockade correlates with genetic
      basis of Juvenile Myelomonocytic Leukemia (JMML) [mutations in NF1, Ras, SHP2] or levels of
      TNFa.

      1.3 Determine if TNF blockade by etanercept results in inhibition of free levels of TNFa and
      other cytokines by ELISA and bioassay and improves blood counts.

      1.4 Estimate the two year event free survival and overall survival in JMML patients following
      etanercept and allogeneic hematopoietic stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Etanercept blocks a hormone called Tumor Necrosis Factor (TNF), which has been shown to play
      a role in helping the growth of leukemic cells in JMML.

      Before participants can start treatment on this study, they will have what are called
      &quot;screening tests&quot;. These tests will help the doctor decide if patients are eligible to take
      part in the study. You will have a complete medical history and physical exam. About two
      tablespoons of blood and urine will be collected for routine tests as well as to test for the
      liver and kidney function. You will have a bone marrow biopsy performed to monitor disease
      activity. To collect a bone marrow biopsy, an area of the hip or chest bone is numbed with
      anesthetic and a small amount of bone marrow and bone is withdrawn through a large needle.
      You will have cells from inside of the mouth tested for genetic changes by swabbing the side
      of the cheeks.

      If you are found to be eligible, etanercept will be given as an injection under the skin once
      a week for up to 90 days.

      During the study, you will have weekly follow-up tests that will include physical exam and
      lab tests. About 2 tablespoons of blood will be collected each time. Urine will also be
      collected for testing at least every 3 weeks while on the study.

      If the disease gets worse or intolerable side effects occur, you will be taken off study and
      alternative treatment options will be discussed.

      This is an investigational study. The FDA has approved etanercept for use in adults and
      children with rheumatoid arthritis and juvenile rheumatoid arthritis. Its use in this study
      is experimental. A total of up to 30 patients will take part in this study. All will be
      enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment; study terminated.
  </why_stopped>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Response is defined as a WBC &lt; 15,000 and platelets &gt; 75,000 at 12 weeks; toxicity is defined as a grade 3 or worse infection or non-hematologic toxicity within the first 4 weeks.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.8 mg/kg subcutaneously weekly for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>0.8 mg/kg Subcutaneously Once A Week for 90 Days</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All children greater than 6 months of age and less than 18 years of age with
             newly-diagnosed previously untreated or previously diagnosed JMML, which has
             reoccurred after treatment with chemotherapy, stem cell transplantation, and/or
             cis-retinoic acid.

          2. A diagnosis of JMML is confirmed only if the following criteria for JMML are met: a)
             ALL of the following: Absence of t(9;22) or BCR-ABL by PCR or FISH; Absolute monocyte
             count &gt;1000 (1 X 109/µL); &lt;20% bone marrow blasts; b) At least 2 of the following:
             Elevated Hb F hemoglobin; Myeloid precursors in peripheral blood; WBC &gt;10,000 (10 X
             109/µL); GM-CSF hypersensitivity in methylcellulose culture of bone marrow progenitors
             cells.

          3. Adequate hepatic function (bilirubin equal or less than 2.0 mg/dl; ALT equal or less
             than 3x normal)

          4. Adequate renal function (serum creatinine equal or less than 2 x normal)

          5. Performance Status: Have a Karnofsky score &gt;50.

          6. Written, informed consent according to institution guidelines.

        Exclusion Criteria:

          1. Pregnant or lactating.

          2. Receiving any other chemotherapy. Patients must have been off chemotherapy for at
             least 2 weeks and must have recovered from acute toxicity of all previous therapy
             prior to enrollment.

          3. Febrile neutropenia at study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J. Wells, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD . Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <results_first_submitted>August 31, 2009</results_first_submitted>
  <results_first_submitted_qc>November 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2010</results_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Juvenile Myelomonocytic Leukemia</keyword>
  <keyword>JMML</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Etanercept</keyword>
  <keyword>Enbrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 05/19/04 through 03/05/09. All participants recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Study was terminated due to low accrual.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Etanercept</title>
          <description>0.8 mg/kg subcutaneously weekly for 90 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etanercept</title>
          <description>0.8 mg/kg subcutaneously weekly for 90 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="3" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Response</title>
        <description>Response is defined as a WBC &lt; 15,000 and platelets &gt; 75,000 at 12 weeks; toxicity is defined as a grade 3 or worse infection or non-hematologic toxicity within the first 4 weeks.</description>
        <time_frame>12 weeks</time_frame>
        <population>No analysis as only registrant inevaluable, and trial terminated early due to poor enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>0.8 mg/kg subcutaneously weekly for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Response</title>
          <description>Response is defined as a WBC &lt; 15,000 and platelets &gt; 75,000 at 12 weeks; toxicity is defined as a grade 3 or worse infection or non-hematologic toxicity within the first 4 weeks.</description>
          <population>No analysis as only registrant inevaluable, and trial terminated early due to poor enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study period 4 years and 10 months. Only patient registered on study for two (2) months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Etanercept</title>
          <description>0.8 mg/kg subcutaneously weekly for 90 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Toxicity</sub_title>
                <description>Grade 3 Non-hematological Toxicity.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to low accrual. Rare disease with less than 100 cases diagnosed per year.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert J. Wells, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-6620</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

